All In Biotech

Drug Trial Radar · NCT07816328

Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

A Global, Multi-center, Open-label Study, Investigating a Remibrutinib- and Omalizumab-Based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-Antihistamines, to Achieve Fast and Well-Controlled Disease Within 24 Weeks

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

382

Planned (sponsor's estimate)

Start

Sep 21, 2026

Primary completion

May 24, 2028

Study completion May 24, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label study is to assess the efficacy and safety of a novel treatment algorithm for sequencing remibrutinib and omalizumab in the treatment of adult participants with chronic spontaneous urticaria (CSU) who are inadequately controlled by second-generation H1-antihistamines (sgH1-AH).

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • RemibrutinibDrug

    Remibrutinib 25 mg twice a day.

  • OmalizumabDrug

    Omalizumab 300 mg every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Urticaria Activity Score over 7 days (UAS7) ≤6 (yes/no)Time frame: Week 24

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Québec, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Hong Kong, Hong Kong, Hong Kong · Recruiting

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Kamimashiki-gun, Kumamoto, Japan · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Hwaseong-si, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.